SI2769980T1 - Derivati pirazolokinolina kot inhibitorji PDE9 - Google Patents
Derivati pirazolokinolina kot inhibitorji PDE9Info
- Publication number
- SI2769980T1 SI2769980T1 SI201230501A SI201230501A SI2769980T1 SI 2769980 T1 SI2769980 T1 SI 2769980T1 SI 201230501 A SI201230501 A SI 201230501A SI 201230501 A SI201230501 A SI 201230501A SI 2769980 T1 SI2769980 T1 SI 2769980T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pde9 inhibitors
- pyrazoloquinoline derivative
- pyrazoloquinoline
- derivative
- pde9
- Prior art date
Links
- UXYHZIYEDDINQH-UHFFFAOYSA-N C1=CNC2=C3C=NN=C3C=CC2=C1 Chemical class C1=CNC2=C3C=NN=C3C=CC2=C1 UXYHZIYEDDINQH-UHFFFAOYSA-N 0.000 title 1
- 229940076380 PDE9 inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161544860P | 2011-10-07 | 2011-10-07 | |
| US201161550623P | 2011-10-24 | 2011-10-24 | |
| US201161558110P | 2011-11-10 | 2011-11-10 | |
| US201161580903P | 2011-12-28 | 2011-12-28 | |
| PCT/JP2012/075748 WO2013051639A1 (ja) | 2011-10-07 | 2012-10-04 | ピラゾロキノリン誘導体 |
| EP12837953.4A EP2769980B1 (en) | 2011-10-07 | 2012-10-04 | Pyrazoloquinoline derivative as pde9 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2769980T1 true SI2769980T1 (sl) | 2016-08-31 |
Family
ID=48043792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201230501A SI2769980T1 (sl) | 2011-10-07 | 2012-10-04 | Derivati pirazolokinolina kot inhibitorji PDE9 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8563565B2 (sl) |
| EP (1) | EP2769980B1 (sl) |
| JP (1) | JP5546693B2 (sl) |
| KR (1) | KR101943680B1 (sl) |
| CN (1) | CN103930423B (sl) |
| AR (1) | AR088235A1 (sl) |
| AU (1) | AU2012319549B2 (sl) |
| BR (1) | BR112014007912B1 (sl) |
| CA (1) | CA2861795C (sl) |
| CL (1) | CL2014000821A1 (sl) |
| CO (1) | CO6910200A2 (sl) |
| CY (1) | CY1117427T1 (sl) |
| DK (1) | DK2769980T3 (sl) |
| ES (1) | ES2568015T3 (sl) |
| HR (1) | HRP20160273T1 (sl) |
| HU (1) | HUE028555T2 (sl) |
| IL (1) | IL231650A (sl) |
| IN (1) | IN2014CN02463A (sl) |
| JO (1) | JO3116B1 (sl) |
| ME (1) | ME02394B (sl) |
| MX (1) | MX358149B (sl) |
| MY (1) | MY167698A (sl) |
| PE (1) | PE20141557A1 (sl) |
| PH (1) | PH12014500580A1 (sl) |
| PL (1) | PL2769980T3 (sl) |
| RS (1) | RS54702B1 (sl) |
| RU (1) | RU2605096C2 (sl) |
| SG (1) | SG11201400717QA (sl) |
| SI (1) | SI2769980T1 (sl) |
| SM (1) | SMT201600108B (sl) |
| TW (1) | TWI562993B (sl) |
| WO (1) | WO2013051639A1 (sl) |
| ZA (1) | ZA201402439B (sl) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104703987B (zh) | 2011-10-10 | 2017-05-03 | H.隆德贝克有限公司 | 具有咪唑并吡嗪酮骨架的pde9抑制剂 |
| PE20151718A1 (es) | 2013-04-05 | 2015-11-22 | Eisai Randd Man Co Ltd | Compuestos piridinilpirazoloquinolina |
| MX359843B (es) * | 2013-04-05 | 2018-10-12 | Eisai R&D Man Co Ltd | Sal de derivado de pirazoloquinolina y cristal de la misma. |
| GB201406486D0 (en) | 2014-04-10 | 2014-05-28 | Redx Pharma Ltd | Antibacterial compounds |
| WO2016021192A1 (en) * | 2014-08-08 | 2016-02-11 | Eisai R&D Management Co., Ltd. | Process for production of (s)-(tetrahydrofuran-3-yl)hydrazine |
| BR112018000254A2 (pt) | 2015-07-07 | 2018-09-04 | H Lundbeck As | inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas |
| WO2017046606A1 (en) * | 2015-09-18 | 2017-03-23 | Redx Pharma Plc | Antibacterial compounds |
| CN107056690A (zh) * | 2017-03-22 | 2017-08-18 | 上海康鹏科技有限公司 | 一种6‑溴吡啶‑3‑甲醛的制备方法 |
| US11147803B2 (en) | 2017-06-01 | 2021-10-19 | Eisai R&D Management Co., Ltd. | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
| JP7293129B2 (ja) | 2017-06-01 | 2023-06-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｐｄｅ９阻害剤を含む医薬組成物 |
| CN110603040B (zh) | 2017-06-01 | 2023-02-28 | 卫材R&D管理有限公司 | 组合吡唑并喹啉衍生物和多奈哌齐的痴呆治疗剂 |
| KR20200010220A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제 |
| EP3743416B1 (en) * | 2018-01-23 | 2023-03-15 | Basf Se | Halogenation of pyridine derivatives |
| HUE065709T2 (hu) | 2018-05-25 | 2024-06-28 | Cardurion Pharmaceuticals Inc | 6-[(3S,4S)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropirán-4-il-7H-imidazo[1,5-a] pirazin-8-on vegyület monohidrát és kristályos formái |
| MA53501A (fr) | 2018-08-31 | 2021-07-07 | Imara Inc | Inhibiteurs de pde9 pour le traitement de la drépanocytose |
| EP3894403A1 (en) | 2018-12-13 | 2021-10-20 | Intervet International B.V. | Process for preparing 1-[(3r,4s)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]p yrazole-4-carboxamide |
| CN114126619B (zh) | 2019-05-09 | 2024-03-15 | 范因斯坦医学研究院 | 用于合成肽模拟物的化合物 |
| US11883461B2 (en) | 2019-05-09 | 2024-01-30 | The Feinstein Institutes For Medical Research | HMGB1 antagonist treatment of severe sepsis |
| CA3139109A1 (en) | 2019-05-09 | 2020-11-12 | The Feinstein Institutes For Medical Research | Hmgb1 antagonist |
| CA3139104A1 (en) | 2019-05-09 | 2020-11-12 | The Feinstein Institutes For Medical Research | Thiosemicarbazates and uses thereof |
| US11530218B2 (en) | 2020-01-20 | 2022-12-20 | Incyte Corporation | Spiro compounds as inhibitors of KRAS |
| EP4135844A1 (en) * | 2020-04-16 | 2023-02-22 | Incyte Corporation | Fused tricyclic kras inhibitors |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| US20230303549A1 (en) | 2020-06-30 | 2023-09-28 | Bayer Aktiengesellschaft | Substituted heteroaryloxypyridines, the salts thereof and their use as herbicidal agents |
| US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
| US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| US12441727B2 (en) | 2021-07-07 | 2025-10-14 | Incyte Corporation | Tricyclic compounds as inhibitors of KRAS |
| JP2024534187A (ja) | 2021-08-31 | 2024-09-18 | インサイト・コーポレイション | Ｋｒａｓの阻害剤としてのナフチリジン化合物 |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| JP2024537824A (ja) | 2021-10-01 | 2024-10-16 | インサイト・コーポレイション | ピラゾロキノリンｋｒａｓ阻害剤 |
| PE20242113A1 (es) | 2021-10-14 | 2024-10-28 | Incyte Corp | Compuestos de quinolina como inhibidores de kras |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2426734C2 (ru) * | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
| WO2005118583A1 (en) * | 2004-05-28 | 2005-12-15 | Millennium Pharmaceuticals, Inc. | 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors |
| CA2622605A1 (en) | 2005-09-15 | 2007-03-22 | Aska Pharmaceutical Co., Ltd. | Heterocycle compound, and production process and application thereof |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| KR101555384B1 (ko) * | 2006-12-13 | 2015-09-23 | 아스카 세이야쿠 가부시키가이샤 | 퀴녹살린 유도체 |
| DK2152712T3 (da) | 2007-05-11 | 2012-03-26 | Pfizer | Aminoheterocykliske fobindelser |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| MX2011009314A (es) * | 2009-03-05 | 2011-10-11 | Astellas Pharma Inc | Compuesto de quinoxalina. |
| GEP20146098B (en) | 2009-03-31 | 2014-05-27 | Boehringer Ingelheim Int | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators |
| US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
| MX2013002584A (es) | 2010-09-07 | 2013-04-29 | Astellas Pharma Inc | Compuesto de pirazoloquinolina. |
| JP6042060B2 (ja) * | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
-
2012
- 2012-10-04 TW TW101136747A patent/TWI562993B/zh active
- 2012-10-04 PE PE2014000408A patent/PE20141557A1/es active IP Right Grant
- 2012-10-04 IN IN2463CHN2014 patent/IN2014CN02463A/en unknown
- 2012-10-04 WO PCT/JP2012/075748 patent/WO2013051639A1/ja not_active Ceased
- 2012-10-04 CA CA2861795A patent/CA2861795C/en active Active
- 2012-10-04 DK DK12837953.4T patent/DK2769980T3/en active
- 2012-10-04 BR BR112014007912-9A patent/BR112014007912B1/pt active IP Right Grant
- 2012-10-04 MY MYPI2014700702A patent/MY167698A/en unknown
- 2012-10-04 KR KR1020147008769A patent/KR101943680B1/ko active Active
- 2012-10-04 RU RU2014112931/04A patent/RU2605096C2/ru active
- 2012-10-04 AU AU2012319549A patent/AU2012319549B2/en active Active
- 2012-10-04 HR HRP20160273TT patent/HRP20160273T1/hr unknown
- 2012-10-04 CN CN201280046653.2A patent/CN103930423B/zh active Active
- 2012-10-04 SI SI201230501A patent/SI2769980T1/sl unknown
- 2012-10-04 MX MX2014003800A patent/MX358149B/es active IP Right Grant
- 2012-10-04 HU HUE12837953A patent/HUE028555T2/en unknown
- 2012-10-04 SG SG11201400717QA patent/SG11201400717QA/en unknown
- 2012-10-04 JO JOP/2012/0302A patent/JO3116B1/ar active
- 2012-10-04 US US13/644,745 patent/US8563565B2/en active Active
- 2012-10-04 JP JP2013537544A patent/JP5546693B2/ja active Active
- 2012-10-04 ME MEP-2016-65A patent/ME02394B/me unknown
- 2012-10-04 EP EP12837953.4A patent/EP2769980B1/en active Active
- 2012-10-04 PH PH1/2014/500580A patent/PH12014500580A1/en unknown
- 2012-10-04 PL PL12837953T patent/PL2769980T3/pl unknown
- 2012-10-04 AR ARP120103702A patent/AR088235A1/es active IP Right Grant
- 2012-10-04 ES ES12837953.4T patent/ES2568015T3/es active Active
- 2012-10-04 RS RS20160232A patent/RS54702B1/sr unknown
-
2013
- 2013-06-11 US US13/914,898 patent/US20130296352A1/en not_active Abandoned
-
2014
- 2014-03-19 CO CO14059034A patent/CO6910200A2/es active IP Right Grant
- 2014-03-20 IL IL231650A patent/IL231650A/en active IP Right Grant
- 2014-04-02 ZA ZA2014/02439A patent/ZA201402439B/en unknown
- 2014-04-03 CL CL2014000821A patent/CL2014000821A1/es unknown
-
2016
- 2016-04-12 CY CY20161100302T patent/CY1117427T1/el unknown
- 2016-04-14 SM SM201600108T patent/SMT201600108B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2769980T1 (sl) | Derivati pirazolokinolina kot inhibitorji PDE9 | |
| IL273079B (en) | Heterocycloamines as pi3k inhibitors | |
| ZA201503041B (en) | Gdf-8 inhibitors | |
| IL228707A0 (en) | History of tetrahydroquinolines used as bromodomain inhibitors | |
| IL233454A (en) | Bromodomain Inhibitors | |
| ZA201306542B (en) | 7-azaindole derivatives | |
| AP3529A (en) | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors | |
| IL231403A0 (en) | Thiazolopyridine compounds as a10pde inhibitors | |
| SI2588457T1 (sl) | Derivati pirazolokinolina kot inhibitorji dna pk | |
| GB201120474D0 (en) | Inhibitors | |
| ZA201308697B (en) | Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors | |
| GB201104399D0 (en) | Novel inhibitors |